By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kite Pharma, Inc. 

2225 Colorado Avenue

Santa Monica  California  90404  U.S.A.
Phone: 301-824-9999 Fax: n/a


Company News
Kite Pharma (KITE) Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society of Hematology 12/6/2016 10:45:33 AM
Kite Pharma (KITE) Initiates Rolling Submission Of U.S. Biologics License Application (BLA) For KTE-C19, Its Investigational Anti-CD19 CAR-T Therapy, For The Treatment Of Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) 12/5/2016 1:07:32 PM
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans 12/5/2016 5:32:45 AM
Kite Pharma (KITE) Appoints Jian Irish, Phd As Senior Vice President Of Supply Chain 12/1/2016 11:08:31 AM
Kite Pharma (KITE) To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society of Hematology Annual Meeting 11/21/2016 11:03:52 AM
Kite Pharma (KITE) Pushes Back Timeline Slightly for Filing of Its Pioneering CAR-T Candidate KTE-C19 11/9/2016 9:14:45 AM
With No Products and a Very Weak Revenue, Here's What Makes Kite Pharma (KITE) So Mighty 11/8/2016 7:08:39 AM
Kite Pharma (KITE) To Report Third Quarter 2016 Financial Results On November 9, 2016 11/2/2016 10:42:58 AM
Watch Out Juno (JUNO) and Kite Pharma (KITE): Novartis AG (NVS) Clearly Not Done With CAR-T 10/25/2016 6:12:56 AM
Kite Pharma (KITE) Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day 10/19/2016 8:51:30 AM